GWPH News and Press, GW Pharmaceuticals Plc From 07/23/19

LONDON, July 23, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will a...

Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...

Listen on the go! Subscribe to The Cannabis Investing Podcast on Libsyn , Spotify , Stitcher or Apple Podcasts . By Rena Sherbill Today, I am very happy to be joined by Dooma Wendschuh. Dooma is co-founder and CEO of Province Brands, a Toronto-based startu...

CannabisNewsWire Editorial Coverage : As hemp production increases, Californian legislators have extended the duration of thousands of cannabis cultivation licenses to support the state’s thriving industry. Sugarmade Inc. (OTCQB: SGMD) ( SGMD Profile ) is supporting many of these c...

U.S. lawmakers weighed reforming pot laws in what advocates called a "historic” hearing on Wednesday, though there didn't appear to be a clear consensus approach, such as giving states the right for legalization, removing weed from schedule 1 of the Controlled Substances Act, or pro...

July 10, 2019 Palm Beach, FL – July 10, 2019 – Consumer buying habits are shifting, as the cannabis industry evolves.  As that happens, investors are being offered incredible opportunities.  For example, according to GMP Securities, “demand for extra...

Since its launch, GW Pharmaceuticals' ( GWPH ) CBD (cannabinoid)-based product, Epidiolex, has been in the news for all the right reasons. And this has propelled the share price by a solid 76.61% in 2019 on a YTD (year-to-date) basis. While past performance is definitely nothing short of exc...

Zogenix ( ZGNX ) had a great day last week, because the FDA had agreed to allow it to resubmit its New Drug Application ((NDA)) for Fintepla for the treatment of seizures associated with Dravet syndrome. This is a major turn of events, especially since many months ago, the stock was crus...

The legal market for cannabis in Canada seems unlikely to be as big as some had projected, certainly for 2019 and possibly beyond. For those holding the ETFMG Alternative Harvest ETF ( MJ ), the size of the Canadian cannabis market is something worth following. This article takes a look at the...

Research into the therapeutic benefits of cannabis is prompting a paradigm shift in many sectors of the healthcare industry. What about medical cannabinoids in pediatric care? When she was just seven months old in June 2013, Sophie Ryan ’s parents learned their daughter had an inoper...